Masters Pharmaceuticals wants its employees to work in a "Google-type atmosphere." So the drug distributor, with a little help from government incentives, will build a $16 million warehouse, distribution center and headquarters in Mason, OH, outside of Cincinnati.
The FDA has rolled up yet another doctor in its campaign to punish practitioners who knowingly bought unapproved foreign drugs on the cheap, taking the risk of giving patients ineffective or even counterfeit medications, which some of them ended up doing.
Mylan is recalling two sterile injectable drugs made in India, including 6 lots of an injectable blood pressure med that it began retrieving after testing found that it might be subpotent and that it missed specifications for impurities and degradation. The second drug is being recalling over a packaging issue.
The European Directorate for the Quality of Medicines has banned products from a Chinese maker of iodine after an inspection at its plant by French inspectors turned up contamination issues in its manufacturing processes, issues with its purified water system and a piece of testing equipment that may have been put in the facility just for show.
Federal authorities in Canada last week raided the Winnipeg headquarters of CanadaDrugs.com but declined to say what prompted the raid, citing a court-ordered confidentiality order.
With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.
Japan's Fujifilm, which snapped up a Texas vaccine manufacturer late last year, says it will pay more than $300 million for a Wisconsin company which has a platform for large-scale human cell production, including a kind of stem cells being used in some promising drug research.
A Sanofi Pasteur facility that was sidelined for more than two years after the FDA discovered mold problems is again producing the bladder cancer drug ImmuCyst/TheraCys, Sanofi's BCG vaccine for tuberculosis, which disappeared from the market after Sanofi shut the plant to do upgrades.
Underwriters Laboratories will train 60 food-and-drug inspectors for India's Gujarat state government so that they begin to assess drug manufacturing plants in the same way that U.S. FDA inspectors do.
California's Alameda County has held fast against Big Pharma pushback to its drug take-back ordinance that requires drugmakers to fund a program for accepting and destroying unused meds. Now San Francisco has passed its own ordinance to require the same thing.
Privately held Tolmar, nearing completion on a manufacturing plant expansion, is now taking on some warehouse space to complement it.
A growing number of patients want, or need, gelatin in the capsules they take that does not come from an animal source, include GMO products or contain other ingredients that might make them sick. Capsule technology specialist Capsugel is now expanding four sites to up its production of vegetarian capsules.
Sun Pharma will start on the hard work now that it has closed on its $4 billion merger of Ranbaxy Laboratories. Managing Director Dilip Shanghvi has pledged that it will get all four of Ranbaxy's sideline plants into 100% compliance with FDA requirements.
After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.
With the approval of the Competition Commission of India, Strides Arcolab will pick up Shasun Pharmaceuticals in a $200 million deal that will expand its manufacturing capabilities and cut its costs and, it hopes, its risks.
India intends to establish 10 drug manufacturing clusters in the country and invest in infrastructure there like water, power and sewer treatment facilities that drugmakers can share in an effort to cut costs.
It has been more than a year and a half since the FDA issued a warning letter for two plants in India owned by Aarti Drugs. But the drugmaker has yet to meet FDA expectations and so the agency has now put them on an import alert, banning them from shipping products to the U.S.
Norwegian drugmaker Weifa figures its consumer health biz and its contract active pharmaceutical ingredient operations both have a better shot at growth if they go their separate ways. To make that happen, Weifa plans on spinning the API business off into a contract manufacturing operation, with its first contract to make the APIs for Weifa.
A Cypriot drugmaker with experience in Vietnam, a market that some Big Pharma players have taken an interest in, has decided on its own expansion there.
G&W Laboratories, a small generic drugmaker, recently broke onto the pharma scene publicly with two substantial deals in 10 months for plants and products. The first deal was last summer when it bought an Actavis plant, and this month it announced a deal to do the same with Teva Pharmaceutical Industries.